ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into...

Read More